Literature DB >> 23863536

Preoperative evaluation of lymphovascular invasion using high-resolution pelvic magnetic resonance in patients with rectal cancer: a 2-year follow-up study.

Yaena Kim1, Jae-Joon Chung, Jeong-Sik Yu, Eun-Suk Cho, Joo Hee Kim.   

Abstract

OBJECTIVES: The objectives of this study were to preoperatively evaluate lymphovascular invasion (LVI) using pelvic magnetic resonance (MR) in patients with rectal cancer and to determine the correlation with distant metastasis rate.
METHODS: If the mesorectal perivascular infiltrative signal was visible on pelvic MR imaging, the possibility of LVI was recorded. Distant metastatic lesions were also recorded at the time of the initial diagnostic workup and over a 2-year follow-up period.
RESULTS: Fifteen (68.2%) of the 22 LVI patients showed mesorectal perivascular infiltrative signals on pelvic MRI. For the prediction of LVI in rectal cancer, MR had a sensitivity of 68.2% and a specificity of 93.2. The initial distant metastasis rate was significantly higher in patients with MR LVI (52%) than in patients without MR LVI (5.7%) (P < 0.0001).
CONCLUSIONS: On pelvic MR, the presence of mesorectal perivascular infiltration by nodes is a specific sign of LVI in rectal cancer, and the presence of LVI is a predictor of distant metastasis.

Entities:  

Mesh:

Year:  2013        PMID: 23863536     DOI: 10.1097/RCT.0b013e31828d616a

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  2 in total

1.  Feasibility of mesorectal vascular invasion in predicting early distant metastasis in patients with stage T3 rectal cancer based on rectal MRI.

Authors:  Young Chul Kim; Jai Keun Kim; Myeong-Jin Kim; Jei Hee Lee; Young Bae Kim; Sung Jae Shin
Journal:  Eur Radiol       Date:  2015-05-28       Impact factor: 5.315

2.  A Novel Multimodal Radiomics Model for Preoperative Prediction of Lymphovascular Invasion in Rectal Cancer.

Authors:  Yiying Zhang; Kan He; Yan Guo; Xiangchun Liu; Qi Yang; Chunyu Zhang; Yunming Xie; Shengnan Mu; Yu Guo; Yu Fu; Huimao Zhang
Journal:  Front Oncol       Date:  2020-04-07       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.